Company: HCTI
Filing Date: 2025-11-21
Form Type: 8-K
Source: 0001213900-25-113672
Chunk: 1

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-21
Form: 8-K
Item: Item 1.01
Chunk 1
---
 the Company entered into a Registration Rights Agreement (the “ RRA”) with the Investors. The RRA requires
the Company to file a registration statement covering the resale of at least 300% of the maximum number of Conversion Shares issuable
at the Floor Price. The filing deadline is the tenth calendar day after signing, and the effectiveness deadline is 60 days after the Filing
Deadline. Failure to meet these deadlines or maintain an effective registration statement results in liquidated damages of 2% per month,
up to a maximum of 20%. The Company has also agreed to use commercially reasonable efforts to obtain stockholder approval for the issuance
of the shares of Common Stock issuable upon pursuant to the Notes in accordance with Nasdaq Listing Rules.

The Offering resulted in gross proceeds to the Company of approximately $6,000,000, before deducting placement agent fees and commissions
and other offering expenses. RBW Capital Partners LLC (a division of Dawson James Securities, Inc.) acted as placement agent for the offering.
As compensation for such placement agent services, the Company has agreed to pay RBW, an aggregate cash fee equal to 8.0% of the gross
proceeds received by the Company, plus $100,000 for its legal fees and expenses.

The foregoing summaries of the Purchase Agreement,
the Notes, and the Registration Rights Agreement are qualified in their entirety by reference to the full text of such agreements, copies
of which are filed as Exhibits 10.1, 4.1, and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation
or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 of this
Current Report on Form 8-K is incorporated herein by reference. The issuance of the Notes will constitute a direct financial obligation
of the Company that is material to the Company.

Item 3.02 Unregistered Sales of Equity Securities.